Biotech Values

[Mufaso]

LBPH- up 200+% mid-day on trial results for Bexicaserin (LP352) in DEEs multiple syndromes) including LGS, Dravet syndrome, SCN2A-related epilepsies, CDD, among others. Longboard Pharmaceuticals was a spinout of the former Arena Pharmaceuticals prior to Arena being purchased by PFE. They focus on GPCRs' for Neurological And Rare Diseases.

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

https://ir.longboardpharma.com/news-releases/news-release-details/longboard-pharmaceuticals-announces-positive-topline-data